Clinical Trials Directory

Trials / Completed

CompletedNCT00826670

Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
58 (actual)
Sponsor
University Hospital, Geneva · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Multidrug-resistant Enterobacteriaceae producing extended-spectrum β-lactamases (hereafter called ESBLs) have emerged as an important cause of bloodstream infection in hospitalized patients and urinary tract infections in the community. As is the case with other multidrug-resistant organisms chronic colonization is frequent, in the case of ESBLs mostly intestinal and urinary carriage. To the investigators knowledge no randomized, placebo-controlled clinical trial has been performed to study the efficacy of a systematic ESBL eradication strategy. Eradication of ESBL carriage would cause benefits for the individual patient - by reducing the risk of infection - and for the community - by reducing transmission. Even if eradication turns out to be impossible, transient suppression of ESBL might reduce the likelihood of transmission and thus still be beneficial from an ecologic perspective. The purpose of the proposed study is to test the hypothesis that the administration of a 10 day course of oral antibiotics active against ESBLs can lead to decolonization of ESBL carriage in hospitalized patients.

Conditions

Interventions

TypeNameDescription
DRUGDecolonizationColistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days
DRUGPlacebo (Decolonization)Placebo

Timeline

Start date
2009-06-01
Primary completion
2012-08-01
Completion
2012-08-01
First posted
2009-01-22
Last updated
2012-08-07

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00826670. Inclusion in this directory is not an endorsement.